SCHEMBL4498553

SCHEMBL4498553

CCOC(=O)c1cnc2ccc(C#N)nc2c1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ NMT1 P30419 3/20 0.44
▸ MAPT P10636 4/20 0.43
▸ DYRK1A Q13627 4/20 0.43
▸ POLB P06746 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ PDE5A O76074 1/20 0.42
▸ NMT2 O60551 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522272 0.87 NMT1 (0.44) NMT1MAPTDYRK1APOLBLMNA
SCHEMBL2280172 0.84 KMT2A (0.54) KMT2AMEN1MAPTDYRK1APOLB
SCHEMBL15615933 0.84 KMT2A (0.54) KMT2AMEN1MAPTDYRK1APOLB
SCHEMBL8330280 0.81 KMT2A (0.52) KMT2AMEN1MAPTDYRK1APOLB
SCHEMBL2802334 0.81 KMT2A (0.52) KMT2AMEN1MAPTDYRK1APOLB
SCHEMBL8326089 0.81 KMT2A (0.52) KMT2AMEN1MAPTDYRK1APOLB
SCHEMBL4511327 0.81 PDE4A (0.36) KMT2AMEN1LMNANPC1RAB9A
SCHEMBL621738 0.81 KMT2A (0.51) KMT2AMEN1MAPTDYRK1ALMNA
SCHEMBL839166 0.76 PDE5A (0.60) KMT2AMEN1NMT1MAPTPDE5A
SCHEMBL9545028 0.76 KMT2A (0.54) KMT2AMEN1MAPTPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 — — US disclosed
EP-1891078-A1 AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2008-02-27 — — EP disclosed
WO-2006125974-A1 AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2006-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity AAAS, AMPD2, AMPD3 KMT2A 889/4885MEN1 1987/4885NMT1 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback